World News: 21:00 GMT Thursday 6th December 2018. [Todos Medical Ltd. via Globe Newswire via SPi World News]
REHOVOT, Israel, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, presented its scientific abstract discussing the most recent clinical trial results of the TM-B1 cancer screen test at the 2018 San Antonio Breast Cancer Symposium (SABCS) earlier today. The TM-B1 cancer screen test, which is designed for women 25 and over, screens for the presence of breast cancer. The study consisted of 190 women, including 50 women with breast cancer (including DCIS).
“We are extremely pleased with the results of our latest clinical trial,” said Herman Weiss, MD, FACOG, MBA, CEO of Todos Medical. “The TM-B1 cancer screen test achieved an overall sensitivity of 86% and specificity of 98% for breast cancer detection in the general population, and interestingly, an 83% sensitivity and 99% specificity was recorded for women with dense breasts (about 55% of study population). In comparison, screening mammography, the most commonly used imaging modality, has a sensitivity and specificity of approximately 80%, and even less in dense breast tissue. These results demonstrate the ability of Todos Medical to offer game-changing technology for the early detection of breast cancer in all women, including those who present challenges to existing screening methods. The potential to save lives is compelling.”
“Our TM-B1 breast cancer screen test, in conjunction with current imaging techniques, may contribute to the early detection of breast cancer by increasing sensitivity and reducing false positive results and unnecessary biopsies,” said Todos Medical Chief Technology Officer Udi Zelig, PhD. “With further studies with larger numbers we hope to validate and establish the utility of adding the TM-B1 cancer screen test to current standard screening for breast cancer. It’s quite an exciting prospect.”
Todos Medical Ltd. (OTCQB: TOMDF) headquartered in Rehovot, Israel, is a cancer in-vitro-diagnostic (“IVD”) company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.
For more information, the content of which is not part of this press release, please visit .
Todos Medical Ltd.Daniel HirschInvestor Relations(347) 699-0029
Globe Newswire: 21:00 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.